Early- and later-stage persistence with antiobesity medications: A retrospective cohort study

• Published in: Obesity (Silver Spring, Md.) Md.), 2024-03, Vol.32 (3), p.486-493
• Main Authors: Gasoyan, Hamlet, Pfoh, Elizabeth R, Schulte, Rebecca, Le, Phuc, Rothberg, Michael B
• Format: Article
• Language: English
• Subjects: Adult; Age; Anti-Obesity Agents - therapeutic use; Body mass index; Chronic illnesses; Cohort analysis; Comorbidity; Diabetes; Drug dosages; Electronic health records; Ethnicity; FDA approval; Gastrointestinal surgery; Humans; Ohio; Patients; Primary care; Regression analysis; Retrospective Studies; Sociodemographics; Weight control; Weight Loss
• ISSN: 1930-7381; 1930-739X; 1930-739X
• DOI: 10.1002/oby.23952

The study's objective was to examine the percentage of patients with an initial antiobesity medication (AOM) fill who were persistent with AOM at 3, 6, and 12 months and to characterize factors associated with persistence at 12 months. This retrospective cohort study used electronic health records from January 2015 to July 2023 in a large health system in Ohio and Florida and included adults with BMI ≥30 kg/m who had an initial AOM prescription filled between 2015 and 2022. The authors identified 1911 patients with a median baseline BMI of 38 (IQR, 34-44). Over time, 44% were persistent with AOM at 3 months, 33% at 6 months, and 19% at 12 months. Across categories of AOM, the highest 1-year persistence was in patients receiving semaglutide (40%). Semaglutide (adjusted odds ratio [AOR] = 4.26, 95% CI: 3.04-6.05) was associated with higher odds of 1-year persistence, and naltrexone-bupropion (AOR = 0.68, 95% CI: 0.46-1.00) was associated with lower odds, compared with phentermine-topiramate. Among patients who were persistent at 6 months, a 1% increase in weight loss at 6 months was associated with 6% increased odds of persistence at year 1 (AOR = 1.06, 95% CI: 1.03-1.09). Later-stage persistence with AOM varies considerably based on the drug and the weight loss at 6 months.